Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical ...
The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...
The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...
The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.
Dr. George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just ...
Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...
Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...
A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...
An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...
A growing number of FDA employees are eyeing the exits as chaos and uncertainty sweep through the agency, according to ...
The latest turmoil within Commissioner Marty Makary’s Food and Drug Administration, an alleged bribery scandal involving a high-level official, is no anomaly. The Sunday resignation of the Center for ...
Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback